In this rapid quantitative assay for pancreatic a-amyiase (EC 3.2.1.1) in serum, we precipitate salivary amylases by b-mm incubationwith monoclonal anti-slivary amylase antibody immobilizedon particlesof polyvinylidenefluoride.We then centrifuge the serum mixture and measure the pancreatic amylase activity remaining in the supemate by a kinetic method. The assay requires 50 /.LLof serum and the standard curve is linear to at least 1300 U of pancreatic amylase per liter of serum. CVs were 1.3% within-run, 6-8% day-to-day. Apparent analytical recovery of pancreatic amylase activity added to serum was 101% ± 2%. Addition of purified salivary amylase, 356 U/L, to sera gave a value for apparent pancreatic amylase of <4 U/L, or 1% of the added salivary amylase activity. This assay correlated well with an electrophoretic method (slope, 0.97-0.99; intercept, 0. A rapid, simple method is needed for precise quantitative measurement of the principal amylase isoenzymes in biological samples (1). Most current methods (2-6) for separating and quantifying amylase isoenzymes are either slow (e.g., electrophoretic and chromatographic methods) or lack absolute specificity (inhibition or differential substrate turnover). Methods based on immunochemical separation of amylase isoenzymes have also been reported (7-10), but with one exception (10), the polyclonal antibodies used in these assays all cross reacted by various degrees with the amylase isoenzymes.
A rapid, simple method is needed for precise quantitative measurement of the principal amylase isoenzymes in biological samples (1). Most current methods (2-6) for separating and quantifying amylase isoenzymes are either slow (e.g., electrophoretic and chromatographic methods) or lack absolute specificity (inhibition or differential substrate turnover). Methods based on immunochemical separation of amylase isoenzymes have also been reported (7-10), but with one exception (10), the polyclonal antibodies used in these assays all cross reacted by various degrees with the amylase isoenzymes.
None of these methods allowed specific measurement of pancreatic amylase.
In contrast, our recent production of a monoclonal antibody that distinguishes between pancreatic and salivary amylases (see Appendix)
provides a tool for immunochemical measurement of the isoenzymes.3 We describe here a 10-mm method for quantitatively removing salivary amylase from serum by absorption onto the monoclonal antibody, which is immobilized on a solid-phase support. This allows the pancreatic isoenzyme to then be measured in a true kinetic assay with an acceptable (less than threefold) dilution of the sample. The precision of the assay and its freedom from clinically important interference, even by relatively large amounts of salivary amylase, should allow more careful study of the potential clinical utility of measurements of pancreatic amylase.
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Received February 4, 1985; accepted May 6, 1985. ). An earlier procedure (13) was modified to enhance the color development and subsequent clarification of the agarose: individual amylase isoenzymes were made visible after electrophoresis by pouring a suspension of dyed-starch particles, prewarmed to 37#{176}C, onto the agarose plate and incubating it at 37 #{176}C for 90 mm in a moist chamber. This suspension was prepared by mixing four tablets of dyed-starch (Phadebas Tablets, prepared with Cibacron Blue F3G-A; Pharmacia Diagnostics, Piscataway, NJ 08854) in 5.5 mL of pH 7.3 buffer (per liter: 5 g of bovine serum albumin, 140 mmol of NaCl, and 10 mmol of NaH2PO4). After the incubation, we washed the agarose plate with distilled water, immersed it in dilute (100 milL) acetic acid for 5 mm, and then collapsed it by warming at 56#{176}C for 30 mm. The colored bands, representing individual amylase isoenzymes, were scanned at 600 mm with an integrating densitometer (Model CDS-200; Beckman Instruments, Irvine, CA 92713). To correct for the differences in activities of the pancreatic and salivary isoenzymes that are observed with the dyed-starch substrate (1), we constructed a response curve for the electrophoretic technique by analysis of known mixtures of pure pancreatic and salivary amylases that we had assayed by the coupled enzymatic method. The pancreatic amylase activity (UIL) of patients' samples was calculated as the total amylase activities of the samples multiplied by the proportion of pancreatic amylase as determined by the electrophoretic procedure.
Materials and Methods

Measurements
Purification of pancreatic and salivary amylase isoenzymes. The various amylase isoenzymes were isolated as previously describe& (14). These preparations were judged to be free of deamidation products because no anodically migrating bands were visible in agarose gel electrophoretograms.
Preparation of immobilized monoclonal antibody (IMAB).
Antibody was fractionally precipitated from mouse ascites fluid with ammonium sulfate and subsequently conjugated to particles of polyvmylidene fluoride according to Newman et al. (15) . The particles were washed four times with pH 7.5 conjugation buffer (20 mmol of Tris and 1.0 g of NaN3 per
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'Samples 2 through 7 wereprepared by mixingvarious relativevolumesof samples I and 8.
Table 3. Effect of Added Salivary Amylase on Pancreatic Amylase Measured in Eight Serac
PancreatIc amylaa., U/I liter) and twice with pH 7.3 phosphate buffer (50 mmol of NaC1, 50 mmol of NaH2PO4, and 100 mL of glycerol per liter). A 300 mLIL suspension of the protein-conjugated particles was stored at 4#{176}C in a pH 7.5 buffer containing, per liter, 20 mmol of Tris, 1.0 g of sodium azide, and 5 g of bovine serum albumin. Typically, a yield of 25 mL of the suspension was obtained from 28 mg of monoclonal antibody.
Immunochemical assay. Gently resuspend the IMAB particles at room temperature by magnetic stirring for 20 mm before beginning the assay. Pipet 50 pL of serum into each of two 2-mL centrifuge tubes labeled "Total" and "Pancreatic." To the "Total" tube, add 100 pL of storage buffer, vortexmix, and incubate at room temperature for 10 miii. To the "Pancreatic" tube add 100 p.L of IMAB suspension, vortexmix, and incubate for 10 miii. Resuspend the contents of the 'Pancreatic" tube twice during the incubation period. Cap both tubes, centrifuge at 1800 x g for 10 miii, and measure amylase activity in both. Multiply the results for the tube marked "Total" by 3.00, to correct for dilution. Multiply the results for the "Pancreatic" tube by 2.83. (The value 2.83, rather than 3.0, is necessary because the IMAB particles occupy a portion of the 100 p.L of suspension added to the 50 pL of serum and this portion does not dilute the amylase.
The value 2.83 was experimentally
determined by measuring the dilution of glucose in 48 sera after addition of IMAB particles. The CV for these determinations was <2%.) Subtract the calculated "Pancreatic" activity value from the calculated "Total" activity to find the estimated "Salivary" activity in the sample.
Estimation of reference ranges. We assayed serum from 51 apparently healthy laboratory workers (mean age 30.5, SD 7.6), 34 of them women, 17 men. Normal reference intervals were estimated with these data by use of a nonparametric technique (16).
Results
Capacity of Immobilized Antibody
In preliminary experiments, we found that each microlitar of the suspension of immobilized antibody removed the equivalent of more than 30 U of salivary amylase per liter from each microliter of serum. In the assay as standardized we used 100 pL of suspension.
Further to establish the particle's capacity, we added salivary amylase to serum at a final activity in excess of 3000 UIL and serially titrated with decreasing quantities of IMAB particles. As shown in Figure 1, lane 2 , the salivary amylase was removed from 50 1zL of this serum by incubation with 100 iL of antibody suspension. As shown in lane 3, no salivary amylase was detectable after the serum was incubated with only 50 pL of
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Other Analytical Variables
Linearity and recovery. We investigated the linearity of the assay and the apparent analytical recovery of amylase by assaying increasing amounts of pancreatic amylase added to a serum pool and by preparing mixtures with different activities by mixing a high-and a low-activity sample in different proportions. As shown in Table 1 , the apparent analytical recovery of added amylase activity was 101±2% at all values tested. The slope of the plot of measured (y) vs expected activity (x) was 1.0. (Table 2) . We evaluated day-to-day precision of the assay by repetitive analysis of sera containing pancreatic amylase at two different levels of activity. These analyses were performed on 22 different days during a month.
Precision
Accuracy.
This assay for pancreatic amylase was only slightly affected by 356 U of added salivary amylase per liter. Approximately 99% of the added salivary activity was removed (Table 3 ). Good correlation was found when we compared results by the present method (y) with those of the electrophoretic method (x), using serum samples from the 51 apparently healthy volunteers (Figure 2) . In a separate Table 4 lists the mean values, standard deviations, and nonparametric reference ranges for total, pancreatic, and salivary amylase. In addition, the percentage of pancreatic amylase was calculated for each subject and the mean, SD, and reference range were determined for this percentage.
Estimated Normal Reference Intervals
Preliminary Clinical Observations
During these studies, we measured pancreatic amylase in serum from a variety of patients. The patients' physicians were unaware of the results. These preliminary observations were consistent with the clinical findings. In three patients acute pancreatitis had been diagnosed. Pancreatic amylase was increased in the serum of all three. In one, the diagnosis of acute pancreatitis was confirmed at the time of partial resection of the pancreas (pancreatic amylase was 80% of total amylase in the serum). In the second, a pseudocyst and choledocholithiasis were documented (pancreatic amylase in serum was 92% of total). In the third, a diagnosis was made on the basis of clinical findings (pancreatic amylase = 97% by the proposed assay, 96% by electrophoresis). Increased pancreatic amylase activities (and proportions) were observed in six additional patients: two with diagnoses of trauma, two with suspected pancreatitis, and two with exposure to toxins. In all six cases, increased pancreatic amylase in serum was also documented by electrophoresis.
In nine other patients who had hyperamylasemia, normal or low values for pancreatic amylase were documented by Table 4 . Estimated Reference Intervals for Amylases In Serum a both methods. The diagnoses for these patients included end-stage renal disease, poorly controlled diabetes, and suspected occult malignancy. The pancreatic amylase fractions as measured by electrophoresis closely agreed with those by the proposed assay.
Discussion
Several features of this procedure (speed, precision, and specificity) merit comparison with pancreatic amylase assays currently in use. This assay can be completed, including measurement of amylase activities, within 40 mm of sample arrival, so the results can be of value in emergency clinical situations. Inhibitor-based assays also have short analysis times, but their dependence upon calibration curves makes them cumbersome, and results are subject to various interpretations.
Methods based on electrophoretic or chromatographic techniques require several hours to perform; they are thus unsuited as emergency assays.
The small within-run precision reflects assay simplicity: a total of four pipetting operations (two manual and two instrumental), which probably determine the ultimate precision of this assay. This assay demonstrates better withinrun precision than do previously reported methods (2, 5, 8, 17) . Between-run precision data are at least comparable (5, 17,18) and generally appear better than those reported (2, 8, 9) for other assays of amylase isoenzymes. In our hands, at least, the precision excels that of any of the immunologicaltype assays for amylase (8) (9) (10) .
The monoclona.l antibody we used in this method is quite specific for salivary amylase. The apparent absence of cross reactivity with pancreatic amylase ( Table 3 ) contrasts with that demonstrated by the protein inhibitor methods (20-25%) and the higher cross reactivities obtained earlier with polyclonal antisera. Indeed, commercial preparations of the protein inhibitor apparently display various cross reactivities (20) , requiring standardization of each new batch of inhibitor before use in the clinical laboratory.
Procedures exploiting differences in substrate turnover (6) also depend upon preparation of a (pancreatic/salivary) calibration curve for interpretation.
The present assay yields results that are linearly related to sample activity concentrations up to and exceeding 1300 U of pancreatic amylase per liter. Samples with high total amylase activity to be assayed by electrophoresis must be diluted before analysis if the pattern is not to be "obscured" by overlap of the bands. As evidenced by results in Table 3 , the extent of carryover for the IMAB assay is <1% when an additional 350 U of salivary amylase per liter has been added to give total amylase activities as high as 800 U/L.
Our antibody is the first mouse monoclonal antibody to salivary amylase. Its specificity and affinity appear to more than adequately meet the needs of the present assay.
Differences in the substrates used for measurement of amylase activity prevent a direct comparison of our reference interval with those reported previously. Our mean percentage pancreatic amylase (49%), however, does agree with those values reported by other investigators. Magid et al. (20) , using agarose electrophoresis to separate amylase isoenzymes, found a mean of 52% pancreatic amylase. Huang and Tietz (5), using a salivary amylase inhibitor, found a mean of 48% pancreatic amylase. Gillard et al. (21) reported a mean of 45% pancreatic amylase for adults.
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The ability specifically and rapidly to distinguish salivary 1 i-so from pancreatic amylases may prove to have considerable
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clinical value. The primary use of measurements of total amylase in serum is to aid in the diagnosis of acute 19-62% pancreatitis. Specific measurements of the pancreatic isoenzyme are sometimes required, because hyperamylasemia
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Activlty,U/L may occur not only in acute pancreatitis but also in disorders such as mumps, trauma to the salivary gland, and tumors of the lung or ovary (22) . In these circumstances the potentially misguided conclusions resulting from total amylase measurements can be avoided by measuring only the pancreatic isoenzyme.
The speed of the assay is potentially of great importance, because acute pancreatitis must be distinguished from various other conditions that often require emergency surgical intervention, in contrast to acute pancreatitis, which usually does not. Laboratory data, to be useful in these decisions, must be made available rapidly. Data that are provided the next day or the day after rarely have an important impact, because by then key clinical decisions have already been made. We hope that our assay procedure will increase the role of amylase isoenzyme measurements in clinical medicine.
